Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis
Open Access
- 25 November 2022
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 12 (12) , 2954
Abstract
Objective: Venous thromboembolism (VTE) is a life-threatening complication that may exacerbate cancer prognosis. Whilst some studies indicate an increased risk of VTE in cancer patients undergoing chemotherapy, the prevalence estimates on the pooled prevalence of VTE in cancer patients undergoing chemotherapy are not known. This study aims to calculate the pooled prevalence of VTE in chemotherapy-treated cancer patients. Methods: Studies on VTE occurrence in cancer patients undergoing chemotherapy were retrieved after database search. The terms used included “cancer”, “chemotherapy”, and “venous thromboembolism”. A random-effects meta-analysis was conducted to obtain a pooled estimate of VTE prevalence in cancer patients undergoing chemotherapy. Results: A total of 102 eligible studies involving 30,671 patients (1773 with VTE, 28,898 without) were included in the meta-analysis. The pooled estimate of VTE prevalence was found to be 6%, ranging from 6% to 7% (ES 6%; 95% CI 6–7%; z = 18.53; p < 0.001). Conclusions: The estimated pooled prevalence rate of VTEs was 6% in cancer patients undergoing CRT, which was higher than the overall crude prevalence rate (5.78%). Comprehensive cancer care should consider stratified VTE risk assessment based on cancer phenotype, given that certain phenotypes of cancer such as bladder, gastric and ovarian posing particularly high risks of VTE.Keywords
This publication has 148 references indexed in Scilit:
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinomaBritish Journal of Cancer, 2013
- Phase II open-label study of sunitinib in patients with advanced breast cancerBreast Cancer Research and Treatment, 2012
- A randomized phase 2 study of temozolomide and bevacizumab or nab‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanomaCancer, 2012
- Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant GliomaJapanese Journal of Clinical Oncology, 2012
- Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapyInvestigational New Drugs, 2012
- Crosstalk between cancer and haemostasisHamostaseologie, 2012
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancerAnnals of Oncology, 2011
- Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapiesInvestigational New Drugs, 2010
- Epidemiology and pathophysiology of cancer-associated thrombosisBritish Journal of Cancer, 2010
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsBlood, 2010